Growth hormone treatment may improve self-esteem and social function in children with short stature.
Genomic testing using next-generation sequencing may be advantageous in diagnosing patients born small for gestational age with persistent short stature.
Primary cancer rates and mortality risk were no higher for pediatric patients treated with growth hormone therapy.
The risk for meningioma was not significantly higher in patients who did not receive radiotherapy.
Investigators sought to improve growth-monitoring programs by examining existing algorithms and examined the effect of using WHO vs national growth charts on algorithm performance.
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Treatment with growth hormone did not affect insulin sensitivity or insulin secretion in girls with Turner syndrome.
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
In larger doses, the diabetes drug may increase height in children and adolescents.
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.